Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2021-01-08

The beginning of the end for Type I diabetes: A new view from immunotherapy science

2020-09-07

Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer

2020-07-28

Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study

2020-03-04

Imcyse Joins Type 1 Diabetes IMI Consortium INNODIA

2019-09-18

Imcyse to present first-in-human phase 1B study results in Type 1 diabetes at EASD 2019

Go Back